Russell Frank Company’s aTyr Pharma ATYR Stock Holding History

Russell Frank Company’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$105K	Buy	+1,907	New	+$145K	﹤0.01%	2784

Other funds holding ATYR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

PVMCV

Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

RIM

RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

GCM

Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

TAM

Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return

Russell Frank Company's ATYR Position: Q1 2016 in Review

Russell Frank Company opened a new position in aTyr Pharma (ATYR) in Q1 2016: 1,907 shares worth $105K. The stake represents ﹤0.01% of the portfolio and ranks #2784 among its holdings.

50 funds tracked by Wall St. Rank hold ATYR as of Q1 2016.

Russell Frank Company held 1,907 shares of aTyr Pharma worth $105K as of Q1 2016.
aTyr Pharma was a new Russell Frank Company position in Q1 2016.
aTyr Pharma made up ﹤0.01% of Russell Frank Company's portfolio in Q1 2016, its #2784 holding.
50 funds tracked by Wall St. Rank held aTyr Pharma as of Q1 2016.

Based on Russell Frank Company's 13F filing for Q1 2016, filed 29 Apr 2016.